Le Lézard
Classified in: Health
Subjects: PDT, TDS, FVT

4C Medical's Novel Mitral Regurgitation Therapy to be Presented at TCT 2017 Shark Tank Innovation Competition


BROOKLYN PARK, Minnesota, Oct. 24, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) will be highlighted in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held October 29-November 2, 2017 in Denver, CO.

Logo - 4C Medical Technologies, Inc.

4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates known issues associated with current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle.

Philippe Généreux, MD, will present "A Novel Trans-catheter Mitral Valve Replacement Technology (4C)" at 8:30 am Tuesday, October 31 in the Colorado Convention Center Four Seasons Ballroom 4. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

"We're excited for Dr. Généreux to present on our technology at TCT, the premier educational meeting for interventional cardiology," said Robert Thatcher, CEO of 4C Medical. "Participating in the Innovation Competition validates the uniqueness of our device, which has potential to provide treatment options for a broad patient population suffering from moderate or severe MR."

About 4C Medical Technologies, Inc.
4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company's implant is the first MR treatment with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle.

Media Contacts
Robert Thatcher
Chief Executive Officer
(612) 600-8951
[email protected]

Jim Flaherty
Chief Financial Officer
(612) 599-0650
[email protected]

Logo - https://mma.prnewswire.com/media/587874/4C_Logo_RGB.jpg


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: